Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
Jad Othman, Ing Soo Tiong, Jenny O’Nions, et al.
Blood (2023) Vol. 143, Iss. 4, pp. 336-341
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
Hartmut Döhner, Courtney D. DiNardo, Frederick Appelbaum, et al.
Blood (2024) Vol. 144, Iss. 21, pp. 2169-2173
Closed Access | Times Cited: 22
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease
Wei‐Ying Jen, Hagop M. Kantarjian, Tapan M. Kadia, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 1, pp. 30-47
Open Access | Times Cited: 18
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2025)
Open Access | Times Cited: 3
Clinico‐Genomic Interrogation of Secondary‐Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies
Jayastu Senapati, Sanam Loghavi, Jennifer Marvin‐Peek, et al.
American Journal of Hematology (2025)
Closed Access | Times Cited: 2
Venetoclax Resistance in Acute Myeloid Leukemia
Sylvain Garciaz, Marie‐Anne Hospital, Yves Collette, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1091-1091
Open Access | Times Cited: 9
Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML
Brunangelo Falini, Richard Dillon
Blood Cancer Discovery (2023) Vol. 5, Iss. 1, pp. 8-20
Open Access | Times Cited: 17
Measurable residual disease (MRD)-testing in haematological and solid cancers
Junren Chen, Robert Peter Gale, Yu Hu, et al.
Leukemia (2024) Vol. 38, Iss. 6, pp. 1202-1212
Open Access | Times Cited: 6
Biology and Management of Acute Myeloid Leukemia With Mutated NPM1
Evan C. Chen, Shai Shimony, Marlise R. Luskin, et al.
American Journal of Hematology (2025)
Closed Access
The Road Not Taken: Exploring Non-Transplant Options in De Novo Philadelphia Positive Acute Myeloid Leukemia.
Mohamed Isam Sharif, Ahmad S. Alotaibi, Ruah Alyamany, et al.
Leukemia Research Reports (2025), pp. 100507-100507
Open Access
Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with NPM1 mutation
Sofie Johansson Alm, Gustav Orrsjö, Giti Shah Barkhordar, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-11
Open Access
Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
Ing Soo Tiong, Sun Loo
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4790-4790
Open Access | Times Cited: 12
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel
Farhad Ravandi, Jacqueline Cloos, Francesco Buccisano, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 12, pp. 1847-1855
Closed Access | Times Cited: 11
Genetic variations in DNA excision repair pathway contribute to the chemosensitivity and prognosis of acute myeloid leukemia
Amin Zhang, Wancheng Liu, Xiaodong Guo, et al.
Clinica Chimica Acta (2024) Vol. 558, pp. 117899-117899
Closed Access | Times Cited: 4
Drug Sensitivity patterns across FAB subtypes and molecular mutations in AML: A comprehensive analysis for precision medicine
Mohan Krishna Shrestha, Bishwas Mandal, Vishal Mandal, et al.
Clinical and Translational Discovery (2025) Vol. 5, Iss. 2
Open Access
SOHO State of the Art Updates and Next Questions: Pre-emptive Therapy at Molecular Measurable Residual Disease Failure in Acute Myeloid Leukemia
Aditya Tedjaseputra, Nigel H. Russell, Richard Dillon
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 11, pp. 737-751
Open Access | Times Cited: 3
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
Jad Othman, Ho Pui Jeff Lam, Sarah Leong, et al.
Deleted Journal (2024) Vol. 1, Iss. 3, pp. 100017-100017
Open Access | Times Cited: 3
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment
Sylvain Garciaz, Pierre‐Yves Dumas, Sarah Bertoli, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 10, pp. 1870-1876
Open Access | Times Cited: 3
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
Firas El Chaer, Anthony J. Perissinotti, Sanam Loghavi, et al.
Leukemia (2024)
Closed Access | Times Cited: 3
MRD in AML: who, what, when, where, and how?
Kieran Sahasrabudhe, Alice S. Mims
Blood (2024) Vol. 143, Iss. 4, pp. 296-298
Open Access | Times Cited: 2
Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions
Jennifer Moritz, Antonia Schwab, Andreas Reinisch, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 599-599
Open Access | Times Cited: 2
Intensive Induction Chemotherapy versus Hypomethylating Agents in Combination with Venetoclax in NPM1-mutant AML
Jan Philipp Bewersdorf, Shai Shimony, Rory M. Shallis, et al.
Blood Advances (2024) Vol. 8, Iss. 18, pp. 4845-4855
Open Access | Times Cited: 2
Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?
Qiujin Shen, Xiaowen Gong, Yahui Feng, et al.
Blood Reviews (2024) Vol. 68, pp. 101226-101226
Open Access | Times Cited: 2
Recent advances in AML with mutated NPM1
Yuichi Ishikawa, Yoko Ushijima, Hitoshi Kiyoi
International Journal of Hematology (2024) Vol. 120, Iss. 5, pp. 556-565
Closed Access | Times Cited: 2
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations
Rabia Shahswar, Arnold Ganser
Expert Review of Hematology (2024) Vol. 17, Iss. 10, pp. 723-739
Closed Access | Times Cited: 2
Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new drug development
Nicholas J. Short, Richard Dillon
American Journal of Hematology (2024)
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top